- Home
- ACIC vs FULC Comparison
ACIC vs FULC Comparison
Compare ACIC & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$12.93
Company Overview
Basic Information| Metric | ACIC | FULC |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 582.7M | 468.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ACIC | FULC |
|---|---|---|
| Price | $12.69 | $12.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 121.7K | ★ 2.6M |
| Earning Date | 11-05-2025 | 10-29-2025 |
| Dividend Yield | ★ 5.92% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $328,331,000.00 | N/A |
| Revenue This Year | $5.03 | N/A |
| Revenue Next Year | $2.40 | N/A |
| P/E Ratio | $7.30 | ★ N/A |
| Revenue Growth | 22.22 | ★ 2752.05 |
| 52 Week Low | $9.97 | $2.32 |
| 52 Week High | $14.25 | $15.74 |
Technical Indicators
Market Signals| Indicator | ACIC | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 65.80 | 61.65 |
| Support Level | $11.91 | $12.56 |
| Resistance Level | $12.30 | $15.32 |
| Average True Range (ATR) | 0.26 | 1.27 |
| MACD | 0.08 | 0.30 |
| Stochastic Oscillator | 100.00 | 60.90 |
Price Performance
Historical Comparison ACIC
FULC
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.